Trial

First/Second Line

N

RR (%)

PFS (mo)

OS (mo)

Ref.

Bevacizumab + paclitaxel

Second

12

16.6

3.7

n.g.

[25]

Bevacizumab + carboplatin + paclitaxel

First

53

17

6

12

[26]

Bevacizumab + carboplatin + paclitacel vs. placebo + carboplatin + paclitaxel

First

214

25.5/16.4

5.6/4.2

12.3/8.6

[9]

Bevacizumab + temozolomide vs bevacizumab + nab-paclitaxel + carboplatin

First

42/51

23.8/33.3

3.8/6.7

12.3/13.9

[27]

Bevacizumab + temozolomide

First

62

16.1

4.2

9.6

[18]

Bevacizumab + nab-paclitaxel

First

50

36

7.6

16.8

[28]

Bevacizumab + ipilimumab

First

46

20

9

25.1

[14]

Bevacizumab + dacarbazine

First

37

19

5.5

11.4

[29]